BR0011538A - Hidroxamidas do ácido 3-(arilsulfonilamino)-tetrahidrofurano-3-carboxìlico - Google Patents

Hidroxamidas do ácido 3-(arilsulfonilamino)-tetrahidrofurano-3-carboxìlico

Info

Publication number
BR0011538A
BR0011538A BR0011538-0A BR0011538A BR0011538A BR 0011538 A BR0011538 A BR 0011538A BR 0011538 A BR0011538 A BR 0011538A BR 0011538 A BR0011538 A BR 0011538A
Authority
BR
Brazil
Prior art keywords
cancer
arylsulfonylamino
tetrahydrofuran
carboxylic acid
treatment
Prior art date
Application number
BR0011538-0A
Other languages
English (en)
Inventor
Lawrence Alan Reiter
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0011538A publication Critical patent/BR0011538A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)

Abstract

Patente de Invenção: " HIDROXAMIDAS DO áCIDO 3-(ARILSULFONILAMINO)-TETRAHIDROFURANO-3-CARBOXìLICO". Um composto da fórmula em que R^ 1^, R^ 2^ e Q são como definidos acima, é útil no tratamento de uma artrite (incluindo osteoartrite e artrite reumatóide), cancro (tal como tumor canceroso sólido incluindo cancro do cólon, cancro da mama, cancro do pulmão e cancro da próstata e malignicidades hematopoiéticas incluindo leucemias e linfomas), e outras perturbações. Além disso, os compostos da presente invenção podem ser usados em terapia de combinação com drogas anti-inflamatórios não esteroidais padrão (NSAID'S) e analgésicos, e em combinação com drogas citotóxicas tais como adriamicina, daunomicina, cis-platina, etoposide, taxol, taxotere e outros alcalóides, tais como vincristina, no tratamento do cancro.
BR0011538-0A 1999-05-28 2000-05-15 Hidroxamidas do ácido 3-(arilsulfonilamino)-tetrahidrofurano-3-carboxìlico BR0011538A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13667799P 1999-05-28 1999-05-28
PCT/IB2000/000646 WO2000073294A2 (en) 1999-05-28 2000-05-15 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides

Publications (1)

Publication Number Publication Date
BR0011538A true BR0011538A (pt) 2002-02-26

Family

ID=22473882

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011538-0A BR0011538A (pt) 1999-05-28 2000-05-15 Hidroxamidas do ácido 3-(arilsulfonilamino)-tetrahidrofurano-3-carboxìlico

Country Status (19)

Country Link
US (1) US6342521B1 (pt)
EP (1) EP1181285B1 (pt)
JP (1) JP3828748B2 (pt)
AT (1) ATE251618T1 (pt)
AU (1) AU4309800A (pt)
BR (1) BR0011538A (pt)
CA (1) CA2375513C (pt)
DE (1) DE60005818T2 (pt)
DK (1) DK1181285T3 (pt)
ES (1) ES2203456T3 (pt)
GT (1) GT200000084A (pt)
HN (1) HN2000000052A (pt)
MA (1) MA26737A1 (pt)
MX (1) MXPA01012266A (pt)
PE (1) PE20010204A1 (pt)
PT (1) PT1181285E (pt)
TN (1) TNSN00114A1 (pt)
UY (1) UY26169A1 (pt)
WO (1) WO2000073294A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP4343373B2 (ja) * 2000-01-14 2009-10-14 富士フイルム株式会社 写真サービスシステム及びデジタルカメラ
AU2001245863A1 (en) * 2000-03-21 2001-10-03 The Procter & Gamble Company Heterocyclic side chain containing metalloprotease inhibitors
PL365444A1 (en) 2000-03-21 2005-01-10 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
AU2001245862A1 (en) 2000-03-21 2001-10-03 The Procter & Gamble Company Difluorobutyric acid metalloprotease inhibitors
US6548539B1 (en) * 2001-03-05 2003-04-15 Avalon Pharmaceuticals Agents for regulation of colon cancer gene expression
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
PE20142099A1 (es) 2009-01-12 2014-12-13 Icagen Inc Derivados de sulfonamida
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5663357A (en) * 1995-11-22 1997-09-02 Allergan Substituted heteroarylamides having retinoid-like biological activity
ID22849A (id) * 1997-01-23 1999-12-09 Hoffmann La Roche Penghambat-penghambat sulmafida-metaloprotease
BR9807815A (pt) * 1997-02-03 2000-03-08 Pfizer Prod Inc Derivados de ácido arilsulfonilamino-hidroxâmico
CA2265671A1 (en) * 1997-07-10 1999-01-21 Daniela Jabes Matrix metalloproteinase inhibitors
IL134273A0 (en) * 1997-07-31 2001-04-30 Procter & Gamble Acyclic metalloprotease inhibitors

Also Published As

Publication number Publication date
MXPA01012266A (es) 2002-07-30
DE60005818T2 (de) 2004-05-06
DE60005818D1 (de) 2003-11-13
WO2000073294A2 (en) 2000-12-07
DK1181285T3 (da) 2004-01-26
PT1181285E (pt) 2004-01-30
US6342521B1 (en) 2002-01-29
GT200000084A (es) 2001-11-17
AU4309800A (en) 2000-12-18
MA26737A1 (fr) 2004-12-20
ATE251618T1 (de) 2003-10-15
JP3828748B2 (ja) 2006-10-04
EP1181285B1 (en) 2003-10-08
UY26169A1 (es) 2000-12-29
JP2003500484A (ja) 2003-01-07
EP1181285A2 (en) 2002-02-27
HN2000000052A (es) 2001-02-02
CA2375513A1 (en) 2000-12-07
TNSN00114A1 (fr) 2002-05-30
PE20010204A1 (es) 2001-03-05
WO2000073294A3 (en) 2001-03-29
ES2203456T3 (es) 2004-04-16
CA2375513C (en) 2006-11-28

Similar Documents

Publication Publication Date Title
DE69925840D1 (de) Tace inhibitoren
YU5201A (sh) Derivati hidroksipipekolathidroksamske kiseline kao inhibitori mmp
EA199900641A1 (ru) Производные арилсульфонилгидроксамовой кислоты
AP9801174A0 (en) Cyclic sulfone derivatives.
CA2279276A1 (en) Arylsulfonylamino hydroxamic acid derivatives
TR200002951T2 (tr) (4-Arilsülfonilamino)-tetrahidropiran-4-karboksilik asit hidroksamitler
BR0011538A (pt) Hidroxamidas do ácido 3-(arilsulfonilamino)-tetrahidrofurano-3-carboxìlico
HK1060067A1 (en) Compositions for antitumour treatment containing ecteinascidin 743
DK1181286T3 (da) 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylsyre hydroxamider
IT8323359A0 (it) Complessi platino-diamminici, procedimento per la loro preparazione, procedimento per lapreparazione di una composizione medica contenente tali complessi platino-diamminici per il trattamento del cancro, nonche'composizione cosi' realizzata.
FI1496918T3 (fi) Natriummeta-arseniitin käyttö kasvainten hoidossa
WO2003096992A3 (en) Treatment of cancer with mefloquire
ECSP003494A (es) Hidroxiamidas de acidos 3- ( arilsulfonilamino)-tetrahidropiran-3-carboxilicos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7O, 8O E 9O ANUIDADES.

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2008 DE 30/06/2009. TEXTO CORRETO: REFERENTE A 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.10 DA RPI 2068 DE 24/08/2010.